Artificial Intelligence in Healthcare
- Bipartisan senators have introduced the Health Tech Investment Act (S. 1399), which would create a Medicare reimbursement pathway for FDA-cleared AI-enabled medical devices. The bill, sponsored by Senators Mike Rounds (R-S.D.) and Martin Heinrich (D-N.M.), would establish a new technology ambulatory payment classification for eligible algorithm-based devices with pricing determined by manufacturer cost data. If approved, AI-enabled services would remain in this classification for at least five years and must have a defined beginning, middle, and end while being distinct from underlying services. This legislation follows another AI healthcare bill (H.R.238) introduced earlier in 2023 that would allow AI systems to autonomously prescribe FDA-approved medications if authorized by states. Source: MobiHealthNews
- Limitations on the current model of AI deployment has given way to a proposal for a new framework for clinical trials of medical AI. The current linear model of AI deployment, where models are trained and then deployed with fixed parameters, is not well-suited for adaptive large language models (LLMs). This paper introduces “dynamic deployment,” a systems-level approach where AI models continuously learn and adapt from new data and user interactions during deployment. This method allows for real-time monitoring and clinical validation, addressing the gap between AI research and real-world patient benefit. While challenges such as infrastructure, cost, and regulation exist, dynamic deployment offers a path for integrating continually learning AI systems into healthcare. Source: NJP Digital Medicine
Fraud & Abuse
- The Seventh and Second Circuits issued opinions narrowing the scope of advertising, marketing, and booking fee activities that violate the federal Anti-Kickback Statute (AKS). In Sorenson, the Seventh Circuit reversed a conviction by ruling that payments to marketing firms for generating leads don’t constitute illegal kickbacks when physicians retain independent judgment and the payments represent compensation for advertising rather than inducement for referrals. Similarly, in Sisselman, the Second Circuit affirmed dismissal of claims against Zocdoc, finding that the company’s reliance on favorable HHS-OIG advisory opinions about its booking fee model defeated the scienter requirement necessary for AKS violations. These rulings establish that marketing activities are not automatically illegal under the AKS when marketers don’t directly influence healthcare decisions and that obtaining favorable advisory opinions can provide protection against both AKS and False Claims Act allegations. Source: Venable
- The U.S. Attorney’s Office for the Southern District of New York announced a $202 million civil False Claims Act settlement with Gilead, resolving allegations that the company’s speaker program violated the Anti-Kickback Statute. Between 2011 and 2017, Gilead paid 548 healthcare providers more than $23.7 million in honoraria, meals, and travel expenses, which prosecutors claimed induced recipients to prescribe Gilead’s HIV medications. The government questioned these programs’ educational value, citing issues including venue selection, alcohol service, and commercial influence on speaker selection, while sales personnel reportedly circumvented meal limits by recording food costs as room fees. This settlement serves as a reminder that authorities analyze speaker program data to identify compliance issues, encouraging companies to implement rigorous controls such as headquarters-based review of speakers and restricting repeat attendance at similar programs. Source: Skadden
- Attorney General Pam Bondi has directed the Department of Justice to investigate pharmaceutical companies and healthcare providers involved in gender transition treatments for potential violations of federal law. The April 22, 2025 memorandum implements Executive Order 14187, which reversed Biden Administration policies supporting gender transition treatments and procedures. The DOJ will pursue potential False Claims Act violations against providers who submit reimbursement claims for gender transition medications or procedures to federal healthcare programs, along with Food, Drug, and Cosmetic Act violations for “off-label” promotion of medications used for transitions. Bondi announced the creation of the Coalition Against Child Mutilation to coordinate with state attorneys general, expressed eagerness to work with qui tam whistleblowers, and stated the DOJ will no longer follow World Professional Association for Transgender Health guidelines. Healthcare and life sciences companies are advised to review promotional materials, billing practices, and internal whistleblowing procedures to mitigate enforcement risks. Source: DLA Piper
- Four individuals have been sentenced to federal prison for orchestrating a $110 million healthcare fraud scheme in Texas. John Rodriguez, a former pharmacist who owned Pharr Family Pharmacy, received 60 months imprisonment while his co-conspirators Mohammad Chowdhury received 30 months, and Hector de la Cruz and Alex Flores each received 46 months. The group paid kickbacks to medical providers who referred prescriptions to Rodriguez’s pharmacy, which then billed federal programs including the Department of Labor, TRICARE, and Medicare. From 2014 to 2016, the pharmacy submitted more than $110 million in claims to federal health care programs for compound drugs, with all defendants now required to serve three years of supervised release following their prison terms. The investigation involved multiple federal agencies including the FBI, with U.S. Attorney Nicholas Ganjei stating that “Illegal kickbacks are the engine that drives health care fraud.” Source: United States Department of Justice
Hospitals
- According to a recent report, hospitals are losing an average of $306,792 per physician annually, representing a 5% increase from the previous year. The financial strain stems from eroding reimbursement advantages, volume-focused incentives that don’t guarantee profitability, and heavy administrative integration costs. The report warns that health systems cannot sustain this financial burden indefinitely. Hospitals are advised to explore alternatives beyond direct physician employment, including ASC joint ventures, transitioning clinics to federally qualified health center look-alikes, and embracing value-based care models. The goal is to maintain market presence while improving financial viability without requiring traditional physician employment structures. Source: Becker’s ASC Review
Legislation
- Two bills were introduced that would create new regulatory requirements for healthcare organizations undergoing ownership, operational, or governance changes. House Bill 2747 would require healthcare entities to notify the Texas attorney general 90 days before material change transactions and authorizes penalties up to $10,000 per violation. Senate Bill 1595 mandates healthcare entities report ownership and control information to the secretary of state annually and during material change transactions, with substantial penalties for non-compliance. The reporting requirements for material change transactions apply to entities with at least $10 million in assets or revenue, with penalties reaching $500,000 per violation for larger organizations. Both bills would take effect September 1, 2025, if passed. Source: King & Spalding
- The Texas House of Representatives has approved two bills designed to facilitate access to psychedelic-assisted therapy once federal approval is granted. The first bill, HB 4014, passed 115-31 and establishes a state-backed study into the use of psilocybin, MDMA, and ketamine for treating conditions like PTSD and depression, with the study to be conducted in consultation with researchers at Baylor College of Medicine and UT Austin. The second bill, HB 4813, passed unanimously and ensures substances reclassified under federal law will be similarly controlled under state law “as soon as practicable,” aimed specifically at expediting access to psychedelic therapies for Texas veterans once FDA approval occurs. The legislation builds on a 2021 measure that studied psychedelics for treating veterans with PTSD, which supporters say helped make Texas “a pioneer in this space.” Source: Marijuana Moment
Life Science
- Private equity firms investing in life science companies face regulatory challenges across multiple domains including AI, fraud enforcement, and pharmaceutical pricing. The Trump Administration has revamped regulatory frameworks through executive orders that mandate agency restructuring and significant deregulation across health agencies. DOJ continues investigating fraud in the sector with heightened scrutiny of investor involvement in portfolio company operations, though establishing FCA liability for sponsors remains legally challenging. New trade policies implementing baseline and reciprocal tariffs affect the healthcare industry, with pharmaceutical imports under national security investigation through Section 232. Medicare drug price negotiations proceed while executive orders seek to lower costs through accelerated approvals for generics and improved drug importation programs. Source: White & Case
Medicare
- The Supreme Court has ruled that hospitals can only count Medicare patients as “entitled to supplemental security income benefits” in their DSH calculations if those patients were eligible for cash SSI payments during their hospitalization month. In the case Advocate Christ Medical Center v. Kennedy, the Court sided with HHS in a 7-2 decision, rejecting arguments from over 200 hospitals that the phrase should include all SSI program enrollees regardless of monthly payment eligibility. The hospitals contended that SSI benefits included non-cash benefits and that eligibility persists throughout enrollment, but the majority found these arguments unpersuasive, stating it “makes little sense to say that individuals are ‘entitled’ to the benefit in months when they are not even eligible for it.” The Court left open whether CMS properly captures all patients eligible for cash payments, while the dissent argued the majority’s interpretation undercounts low-income patients served by hospitals. Source: King & Spalding
Non-Competes
- Several states have enacted legislation taking effect in 2025 that restricts noncompete agreements for healthcare workers. Arkansas will ban physician noncompetes completely while Louisiana limits them to three years for primary care physicians and five years for other physicians. Maryland restricts noncompetes to one year and within ten miles for healthcare workers earning under $350,000, while Pennsylvania caps them at one year for doctors and certain nursing professionals. Utah prohibits “health care services platforms” from requiring noncompetes, joining states like Texas, Florida, and Colorado that already have established limitations on physician noncompete agreements. Source: Foley & Lardner
Nursing
- A survey by the Texas Center for Nursing Workforce Studies shows three out of four Texas nurses experienced violence, sexual harassment, or verbal abuse in the past year. Violence against nurses has increased since 2016, with physical assaults rising from 25% to 35% and sexual harassment from 23.5% to 33%. Hospital nurses face the highest risk, with 93% reporting workplace violence during their careers, causing 40% to consider changing jobs and 25% to plan leaving the profession. Nurses cite lack of respect, patient expectations, and staffing shortages as primary causes for the increase in violence. Texas passed a law in 2023 requiring healthcare facilities to implement violence prevention plans and training, though many nurses still don’t report incidents because they believe nothing will change. Source: Houston Chronical